Ticker
ACHL

Price
3.10
Stock movement up
+0.10 (3.33%)
Company name
Achilles Therapeutics PLC ADR
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
126.39M
Ent value
-84.81M
Price/Sales
-
Price/Book
0.47
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-50.40%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

ACHL does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book0.47
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count40.77M
EPS (TTM)-1.59
FCF per share (TTM)-0.91

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-69.46M
Net income (TTM)-64.69M
EPS (TTM)-1.59
EPS (1y forward)-2.09

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash236.93M
Net receivables14.46M
Total current assets259.05M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets292.19M
Accounts payable4.04M
Short/Current long term debt11.88M
Total current liabilities17.85M
Total liabilities25.73M
Shareholder's equity266.45M
Net tangible assets266.45M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-32.96M
Capital expenditures (TTM)4.04M
Free cash flow (TTM)-37.00M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-24.28%
Return on Assets-22.14%
Return on Invested Capital-24.28%
Cash Return on Invested Capital-13.89%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open3.00
Daily high3.14
Daily low3.00
Daily Volume21K
All-time high17.86
1y analyst estimate14.33
Beta-
EPS (TTM)-1.59
Dividend per share-
Ex-div date-
Next earnings date7 Nov 2022

Downside potential

Loading...
Downside potential data
ACHLS&P500
Current price drop from All-time high-82.64%-13.41%
Highest price drop-89.03%-56.47%
Date of highest drop9 May 20229 Mar 2009
Avg drop from high-65.96%-11.38%
Avg time to new high177 days12 days
Max time to new high351 days1805 days
COMPANY DETAILS
ACHL (Achilles Therapeutics PLC ADR) company logo
Marketcap
126.39M
Marketcap category
Small-cap
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Employees
242
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
The European Commission approves Gilead's (GILD) CAR T-cell therapy, Tecartus, for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
September 7, 2022
The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplasti...
August 31, 2022
Kodiak Sciences (KOD) has progressed well with the development of its lead pipeline candidate, tarcocimab, for treating various retinal vascular diseases.
August 26, 2022
The Japanese Ministry of Health, Labour, and Welfare approved AstraZeneca's (AZN) three marketed drugs, Lynparza, Tagrisso and Ultomiris, for three different indications in Japan.
August 25, 2022
Amgen's (AMGN) phase III study evaluating ABP 959, a biosimilar candidate to Soliris for treating paroxysmal nocturnal hemoglobinuria, meets the primary endpoint.
August 24, 2022
Horizon's (HZNP) portfolio of marketed drugs, including Tepezza and Krystexxa, aid growth. The company is also working on the label expansion of its drugs. However, stiff competition remains a woe.
August 23, 2022
Kodiak Sciences (KOD) lead pipeline candidate, tarcocimab, being developed for treating various retinal vascular diseases, holds potential. Stiff competition in the market remains a woe.
August 19, 2022
Horizon (HZNP) enters into a collaboration and option agreement with Q32 Bio to develop the latter's ADX-914 for treating autoimmune diseases.
August 16, 2022
- Additional clinical data from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) expected to be available in Q4 2022 - - Cell & Gene Therapy Catapult manufacturing facil...
August 9, 2022
If you want to know who really controls Achilles Therapeutics plc ( NASDAQ:ACHL ), then you'll have to look at the...
August 1, 2022
Next page